Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.
Haematologica
; 96(7): 1072-6, 2011 Jul.
Article
in En
| MEDLINE
| ID: mdl-21393326
ABSTRACT
This trial evaluated the feasibility and efficacy of the infusion of mesenchymal stem cells expanded using human serum for the treatment of refractory acute or chronic graft-versus-host disease. Twenty-eight expansions were started. In 22, a minimum of more than 1 x 106 mesenchymal stem cells/kg were obtained after a median of 26 days; this threshold was not obtained in the remaining cases. Ten patients received cells for the treatment of refractory or relapsed acute graft-versus-host disease and 8 for chronic disease. One patient treated for acute graft-versus-host disease obtained a complete response, 6 had a partial response and 3 did not respond. One of the chronic patients achieved complete remision, 3 a partial response, and 4 did not respond. The current study supports the use of this approach in less heavily treated patients for both acute and chronic graft-versus-host disease. The trial has been registered at ClinicalTrials.gov identifier NCT00447460.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Serum
/
Mesenchymal Stem Cell Transplantation
/
Mesenchymal Stem Cells
/
Graft vs Host Disease
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Haematologica
Year:
2011
Document type:
Article
Affiliation country:
Spain